Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares Ultra Bitcoin ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while ProShares Ultra Bitcoin ETF trades at $9.02. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BITU | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $64.41 |
52-Week Low | $10.24 | $8.12 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BITU trades at $9.48, up 7.36% in the last 24 hours, with a bullish technical signal but bearish moving averages. The stock faces structural challenges as a leveraged ETF, with key financial ratios like P/E and P/S unavailable. Recent news highlights underperformance relative to Bitcoin due to daily rebalancing decay, with Seeking Alpha rating it a Hold on June 16, 2026.
Outlook remains cautious due to BITU's leveraged structure and volatility decay risks. Investment opportunities are limited to short-term tactical plays during clear bull markets, but long-term holders face significant erosion. Primary risks include ETF mechanics, Bitcoin price dependency, and investor sentiment shifts amid crypto volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
